Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 7/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.36 |
| ▸ | PRF1 | P14222 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5126253 | 0.76 | PGR (0.43) | PGRCHEK1CREBBPLRRK2PRF1 | |
| SCHEMBL5111338 | 0.72 | PGR (0.45) | PGRCHEK1CREBBPLRRK2PRF1 | |
| SCHEMBL4845544 | 0.70 | IL1RN (0.33) | — | |
| SCHEMBL5126205 | 0.69 | FADS1 (0.43) | PGRCHEK1CREBBPCETP | |
| SCHEMBL5114490 | 0.67 | PGR (0.38) | PGRCHEK1CREBBP | |
| SCHEMBL5112199 | 0.65 | PGR (0.65) | PGRCHEK1CREBBP | |
| SCHEMBL5126385 | 0.65 | PGR (0.44) | PGRCHEK1CREBBPLRRK2PRKCQ | |
| SCHEMBL3870155 | 0.62 | PGR (0.76) | PGRCHEK1 | |
| SCHEMBL2527868 | 0.61 | CLK4 (0.49) | PGRCHEK1CREBBPLRRK2PRF1 | |
| SCHEMBL3310037 | 0.61 | CYP11B1 (0.58) | PGRCHEK1CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435733-B2 | Mineralocorticoid receptor modulator compounds and methods, and pharmaceutical compositions containing these compounds | LIGAND PHARMACEUTICALS, INC. (US) | 2008-10-14 | — | — | US | claimed |
| US-20070185102-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | LIGAND PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | claimed |
| US-7435733-B2 | Mineralocorticoid receptor modulator compounds and methods, and pharmaceutical compositions containing these compounds | LIGAND PHARMACEUTICALS, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20070185102-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | LIGAND PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185102-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | NR3C2, MC2R, NR3C1 | PGR 176/4885CHEK1 4457/4885CREBBP 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.